Cogent Biosciences Inc

NASDAQ:COGT   10:46:40 AM EDT
8.10
-0.20 (-2.41%)
Products, Regulatory

Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib As A Differentiated Kit Inhibitor With Minimal Brain Penetration

Published: 10/07/2021 13:12 GMT
Cogent Biosciences Inc (COGT) - Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib As a Differentiated Kit Inhibitor With Minimal Brain Penetration.
Cogent Biosciences - Currently Enrolling Apex, a Phase 2 Clinical Study of Bezuclastinib (cgt9486) for Patients With Advanced Systemic Mastocytosis.
Cogent Biosciences Inc - on Track to Initiate Clinical Trials of Bezuclastinib for Patients With Nonadvsm & Gastrointestinal Stromal Tumors in 2021.